Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc., a leading biopharmaceutical company headquartered in the United States, is renowned for its innovative therapies in the field of rare diseases. Founded in 1992, Alexion has made significant strides in developing life-changing treatments, particularly in the areas of neurology, nephrology, and immunology.
The company’s flagship products, including Soliris and Ultomiris, are unique in their ability to target complement-mediated diseases, setting new standards in patient care. With a strong market position, Alexion has achieved notable milestones, such as expanding its global reach across North America, Europe, and Asia. Committed to advancing science and improving patient outcomes, Alexion Pharmaceuticals continues to be a pivotal player in the biopharmaceutical industry.
+57 vs industry average
Alexion Pharmaceuticals, Inc.’s score of 95 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Alexion Pharmaceuticals, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Reported emissions
No reported emissions data is available for Alexion Pharmaceuticals, Inc. yet.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Alexion Pharmaceuticals, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Alexion Pharmaceuticals, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Inherited from AstraZeneca PLC
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Inherited from AstraZeneca PLC
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Alexion Pharmaceuticals, Inc.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project